CompletedNot Applicable

Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome

Japan2,016 participantsStarted 2005-05

Plain-language summary

This study is conducted in Japan. The aim of this study is to collect information about the efficacy and safety of Norditropin® (somatropin) in the long-term treatment of short stature with GHD (Growth Hormone Deficiency) where epiphysial discs are not closed and short stature with Turner Syndrome where epiphysial discs are not closed.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Growth hormone deficiency or short stature due to Turner Syndrome where the epiphyseal discs are not closed Exclusion Criteria: * Diabetic * Patients with malignant tumors * Women who are either pregnant or likely to be pregnant * Known or suspected allergy to study product(s) or related products

What they're measuring

Change from baseline in height

Timeframe: Week 0, Month 36, final height is reached

Incidence of adverse reactions (ADRs)

Timeframe: 36 months, accumulation of study period

Trial details

NCT IDNCT01604161

SponsorNovo Nordisk A/S

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2015-06

View on ClinicalTrials.gov More Growth Hormone Disorder trials